Skip to content
10-K

Annual Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-001082

← back to feed
Filed
Jun 17, 2026 12:15 PM ET
Period of report
Jun 17, 2026

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2026 · Jun 17, 2026 207.03M sh
Shares Diluted FY 2026 · Jan 31, 2026 207.03M sh
Shares Diluted FY 2026 · Jan 31, 2025 207.03M sh
Operating Cash Flow FY 2026 · Jan 31, 2026 −$2.69K
Operating Cash Flow FY 2026 · Jan 31, 2025 −$14.68K
Stockholders Equity FY 2026 · Jan 31, 2026 −$4.43M
Stockholders Equity FY 2026 · Jan 31, 2025 −$4.02M
Stockholders Equity FY 2026 · Jan 31, 2024 −$3.35M
Current Liabilities FY 2026 · Jan 31, 2026 $4.45M
Current Liabilities FY 2026 · Jan 31, 2025 $4.03M
Total Liabilities FY 2026 · Jan 31, 2026 $4.45M
Total Liabilities FY 2026 · Jan 31, 2025 $4.03M
Current Assets FY 2026 · Jan 31, 2026 $10.53K
Current Assets FY 2026 · Jan 31, 2025 $272
Total Assets FY 2026 · Jan 31, 2026 $14.68K
Total Assets FY 2026 · Jan 31, 2025 $14.38K
Eps Diluted FY 2026 · Jan 31, 2026 $0.00
Eps Diluted FY 2026 · Jan 31, 2025 $0.00
Sga Expense FY 2026 · Jan 31, 2026 $385.41K
Sga Expense FY 2026 · Jan 31, 2025 $679.91K
Net Income FY 2026 · Jan 31, 2026 −$415.37K
Net Income FY 2026 · Jan 31, 2025 −$774.92K
Operating Income FY 2026 · Jan 31, 2026 −$385.41K
Operating Income FY 2026 · Jan 31, 2025 −$679.91K
Gross Profit FY 2026 · Jan 31, 2026 $0
Gross Profit FY 2026 · Jan 31, 2025 $0
Cost Of Revenue FY 2026 · Jan 31, 2026 $0
Cost Of Revenue FY 2026 · Jan 31, 2025 $0
Revenue FY 2026 · Jan 31, 2026 $0
Revenue FY 2026 · Jan 31, 2025 $0